Benign Hematology: Review Questions

Series Editor:
Eric D. Jacobsen, MD
Instructor of Medicine, Harvard Medical School, Boston, MA;
Attending Physician, Dana-Farber Cancer Institute, Boston, MA

Contributor:
Anaadriana Zakarija, MD
Assistant Professor of Medicine, Division of Hematology/Oncology,
Feinberg School of Medicine, Northwestern University, Chicago, IL

Table of Contents

Questions ........................................... 2
Answers and Explanations ....................... 6
References ........................................ 11

Cover Illustration by Kathryn K. Johnson

Copyright 2008, Turner White Communications, Inc., Strafford Avenue, Suite 220, Wayne, PA 19087-3391, www.turner-white.com. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, mechanical, electronic, photocopying, recording, or otherwise, without the prior written permission of Turner White Communications. The preparation and distribution of this publication are supported by sponsorship subject to written agreements that stipulate and ensure the editorial independence of Turner White Communications. Turner White Communications retains full control over the design and production of all published materials, including selection of topics and preparation of editorial content. The authors are solely responsible for substantive content. Statements expressed reflect the views of the authors and not necessarily the opinions or policies of Turner White Communications. Turner White Communications accepts no responsibility for statements made by authors and will not be liable for any errors of omission or inaccuracies. Information contained within this publication should not be used as a substitute for clinical judgment.

www.turner-white.com

HEMATOLOGY BOARD REVIEW MANUAL

STATEMENT OF EDITORIAL PURPOSE
The Hospital Physician Hematology Board Review Manual is a study guide for fellows and practicing physicians preparing for board examinations in hematology. Each manual reviews a topic essential to the current practice of hematology.

PUBLISHING STAFF
PRESIDENT, GROUP PUBLISHER
Bruce M. White
EDITORIAL DIRECTOR
Debra Dreger
ASSOCIATE EDITOR
Rita E. Gould
ASSISTANT EDITOR
Farrawh Charles
EXECUTIVE VICE PRESIDENT
Barbara T. White
EXECUTIVE DIRECTOR OF OPERATIONS
Jean M. Gaul
PRODUCTION DIRECTOR
Suzanne S. Banish
PRODUCTION ASSISTANT
Nadja V. Frist
ADVERTISING/PROJECT DIRECTOR
Patricia Payne Castle
SALES & MARKETING MANAGER
Deborah D. Chavis

NOTE FROM THE PUBLISHER:
This publication has been developed without involvement of or review by the American Board of Internal Medicine.
Benign Hematology: Review Questions

Anaadriana Zakarija, MD

QUESTIONS

Choose the single best answer for each question.

1. A 28-year-old man presents for follow-up and further evaluation of a recent thrombotic event. Three months ago, the patient presented to the emergency department (ED) with mild shortness of breath occurring at rest that developed a few hours prior to presentation and a 2-day history of dyspnea with exertion. He denied fever and cough, and there was no lower extremity edema. Past medical history was significant for cholecystectomy that occurred 2 weeks before the ED presentation. The patient was not taking any medications. Physical examination conducted in the ED was notable for a heart rate of 102 bpm. On auscultation, crackles were appreciated at the right base of the lungs. Computed tomography scan of the chest demonstrated a thrombus in the right lower lobe segmental pulmonary artery. The patient was admitted to the hospital. Thrombophilia evaluation was subsequently performed, which revealed a positive lupus anticoagulant, antiphospholipid antibodies; factor V Leiden [FVL] and prothrombin G20210A gene mutations; and protein C, protein S, and antithrombin activity) performed at the time of diagnosis was negative. The patient has never taken any hormonal contraceptives. Which of the following is the most appropriate recommendation for this patient during her pregnancy?

(A) Warfarin with target INR of 2 to 3 for 6 months
(B) Indefinite warfarin with target INR of 2 to 3
(C) Indefinite warfarin with target INR of 2.5 to 3.5 for 3 to 6 months
(D) Warfarin with target INR of 2.5 to 3.5 for 3 to 6 months

2. A 32-year-old woman is referred for consultation in regards to anticoagulation prophylaxis during pregnancy. Five years ago, the patient experienced a deep vein thrombosis (DVT) of the right popliteal vein 11 days after laparoscopic surgery of the right knee. At that time, the patient was treated initially with enoxaparin and transitioned to warfarin (target INR, 2–3) for 6 months. Thrombophilia evaluation (which included evaluation for lupus anticoagulant; anticardiolipin and β2-glycoprotein I antibodies; factor V Leiden [FVL] and prothrombin G20210A gene mutations; and protein C, protein S, and antithrombin activity) performed at the time of diagnosis was negative. The patient has never taken any hormonal contraceptives. Which of the following is the most appropriate recommendation for this patient during her pregnancy?

(A) Aspirin 81 mg/day
(B) Prophylactic dose of a low-molecular-weight heparin (LMWH) plus aspirin
(C) Prophylactic dose of a LMWH starting at 8 weeks of gestation
(D) No treatment antepartum

3. A 64-year-old man is referred by his primary care physician for evaluation of anemia and leukopenia. The patient reports that he has experienced mild fatigue and decreased exercise tolerance for the last 6 months. Both review of systems and physical examination are unremarkable. Past medical history is significant for hypertension, psoriasis, and benign prostatic hypertrophy. The patient’s medications include amlodipine, atenolol, tamsulosin hydrochloride, zinc, a multivitamin, and vitamin E supplement. Laboratory studies are ordered, and notable results are listed in Table 1. Bone marrow biopsy is performed, which reveals a normocellular marrow with adequate megakaryocytes, erythroid, and myeloid precursors. Representative myeloid and erythroid precursors are seen in Figure 1 (see page 4). Cytogenetic analysis reveals normal male